A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis C

NCT01482390 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C

Interventions

DRUG: Ribavirin
DRUG: Mericitabine
DRUG: Peginterferon Alfa-2a
DRUG: Placebo
DRUG: Telaprevir

Sponsor

Hoffmann-La Roche